← Eichor
Condition: Acute Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06245746Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06874257Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06232694Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06754267Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy
Phase N/A · 3 location(s) · Centre Hospitalier Universitaire, Amiens · NCT03450512A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considerin
NA · 1 location(s) · Columbia University · NCT05963971A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With A
Phase 2 · 19 location(s) · Shanghai Tong Ren Hospital · NCT05736965Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06481241Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma
NA · 1 location(s) · St. Jude Children's Research Hospital · NCT06747910Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06511882VA vs DA for Newly Diagnosed Hig-risk AML
Phase 2/Phase 3 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT05939180MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NA · 1 location(s) · King Hussein Cancer Center · NCT07371403Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditionin
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06557161MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Phil
EARLY_Phase 1 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07074496Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07490288A Study of CTD402 in T-ALL/LBL Patients
Phase 1/Phase 2 · 8 location(s) · Imviva Bio · NCT07070219A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Phase 1 · 1 location(s) · Nanjing Chia-tai Tianqing Pharmaceutical · NCT06049667Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lym
Phase 2 · 8 location(s) · City of Hope Medical Center · NCT06918431Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054EWALL-PH OBSERVARTORY 2022
Phase N/A · 23 location(s) · Versailles Hospital · NCT07684131In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 2 · 1 location(s) · University of Manitoba · NCT06599762Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute M
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT06484062Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/Phase 3 · 12 location(s) · Merck Sharp & Dohme LLC · NCT07570173Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Im
Phase 1 · 22 location(s) · Taiho Oncology, Inc. · NCT04953910Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia
Phase N/A · 7 location(s) · Carevive Systems, Inc. · NCT05974150
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.